Evidence map›Paper›PMID 41826598›Full record

ArticleDiscover oncology2026

Multi-omics integration reveals tumor and microenvironmental heterogeneity in malignant pleural mesothelioma.

Hai Hu, Lulu Li, Wei Bian, Xiuhua Wu

Abstract read
In one paragraph

Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hai Hu *Department of Respiratory and Clinical Care Medicine, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 600 Yishan Road, Shanghai, 200233, China.
Lulu Li *Department of Respiratory and Clinical Care Medicine, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 600 Yishan Road, Shanghai, 200233, China.
Wei BianDepartment of Respiratory and Clinical Care Medicine, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 600 Yishan Road, Shanghai, 200233, China.
Xiuhua WuDepartment of Respiratory and Clinical Care Medicine, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 600 Yishan Road, Shanghai, 200233, China. wuxiuhua627@163.com.

Funding

Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine ynts202006
6 · The paper itself

Abstract

Malignant pleural mesothelioma (MPM) is a highly aggressive and molecularly heterogeneous malignancy with poor prognosis. Here, we performed an integrative multi-omic analysis combining bulk transcriptomics, copy number variation profiling, and single-cell RNA sequencing to systematically characterize MPM heterogeneity. Using non-negative matrix factorization, we identified three robust molecular subtypes (S-I, S-II, and S-III) with distinct transcriptional programs, genomic alterations, and tumor microenvironment compositions. Subtype S-I exhibited immune-inflamed signatures with abundant cytotoxic T cells and activated dendritic cells, suggesting potential responsiveness to immunotherapy. S-II was characterized by metabolic reprogramming and mTORC1 pathway activation, whereas S-III displayed stromal enrichment, extracellular matrix remodeling, and suppressed apoptotic signaling. Single-cell analysis revealed subtype-specific distributions of malignant and stromal cell subsets, corroborating bulk-level observations and highlighting intratumoral heterogeneity. Collectively, these findings refine the molecular classification of MPM, uncover subtype-specific regulatory programs, and identify potential therapeutic vulnerabilities, providing a framework for precision medicine strategies in this challenging malignancy.

Indexed as

HeterogeneityMalignant pleural mesothelioma (MPM)Molecular subtypesSingle-cell RNA sequencingTumor microenvironment

Identifiers

PMID41826598
PMCPMC13100185

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.